特异性人类白细胞抗原等位基因与甲状腺免疫相关不良事件发生之间的关系。

IF 2.7 4区 医学 Q3 IMMUNOLOGY
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-06-18 DOI:10.1080/1750743X.2024.2353539
Eisaku Sasaki, Yutaka Natori, Emi Tokuda, Reiko Kimura-Tsuchiya, Junko Suga, Kenya Kanazawa, Tomoyuki Koguchi, Nobuyuki Kikuchi, Naoyuki Okabe, Shigeyuki Murono, Kazunoshin Tachibana, Shu Soeda, Michio Shimabukuro, Shigehira Saji
{"title":"特异性人类白细胞抗原等位基因与甲状腺免疫相关不良事件发生之间的关系。","authors":"Eisaku Sasaki, Yutaka Natori, Emi Tokuda, Reiko Kimura-Tsuchiya, Junko Suga, Kenya Kanazawa, Tomoyuki Koguchi, Nobuyuki Kikuchi, Naoyuki Okabe, Shigeyuki Murono, Kazunoshin Tachibana, Shu Soeda, Michio Shimabukuro, Shigehira Saji","doi":"10.1080/1750743X.2024.2353539","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Inherent variations in human leukocyte antigen (HLA) alleles have been revealed epidemiologically to influence the development of autoimmune diseases. HLA alleles may thus also be associated with the development of immune-related adverse events (irAEs), such as thyroid irAE.<b>Materials & methods:</b> In this case-control study, 71 cancer patients who received immune checkpoint inhibitors were enrolled and HLA-genotyped and the frequency of HLA alleles was compared.<b>Results:</b> <i>A*26:01</i>, <i>DPA1*01:03</i> and <i>DPB1*02:01</i> were significantly more frequent in patients with thyroid irAE than in patients without any irAEs (35.0 vs 3.2% [<i>p</i> = 0.004], 80.0 vs 45.2% [<i>p</i> = 0.020] and 55.0 vs 25.8% [<i>p</i> = 0.044], respectively).<b>Conclusion:</b> <i>A*26:01</i>, <i>DPA1*01:03</i> and <i>DPB1*02:01</i> appear to be associated with thyroid irAE.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"723-732"},"PeriodicalIF":2.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421297/pdf/","citationCount":"0","resultStr":"{\"title\":\"Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event.\",\"authors\":\"Eisaku Sasaki, Yutaka Natori, Emi Tokuda, Reiko Kimura-Tsuchiya, Junko Suga, Kenya Kanazawa, Tomoyuki Koguchi, Nobuyuki Kikuchi, Naoyuki Okabe, Shigeyuki Murono, Kazunoshin Tachibana, Shu Soeda, Michio Shimabukuro, Shigehira Saji\",\"doi\":\"10.1080/1750743X.2024.2353539\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> Inherent variations in human leukocyte antigen (HLA) alleles have been revealed epidemiologically to influence the development of autoimmune diseases. HLA alleles may thus also be associated with the development of immune-related adverse events (irAEs), such as thyroid irAE.<b>Materials & methods:</b> In this case-control study, 71 cancer patients who received immune checkpoint inhibitors were enrolled and HLA-genotyped and the frequency of HLA alleles was compared.<b>Results:</b> <i>A*26:01</i>, <i>DPA1*01:03</i> and <i>DPB1*02:01</i> were significantly more frequent in patients with thyroid irAE than in patients without any irAEs (35.0 vs 3.2% [<i>p</i> = 0.004], 80.0 vs 45.2% [<i>p</i> = 0.020] and 55.0 vs 25.8% [<i>p</i> = 0.044], respectively).<b>Conclusion:</b> <i>A*26:01</i>, <i>DPA1*01:03</i> and <i>DPB1*02:01</i> appear to be associated with thyroid irAE.</p>\",\"PeriodicalId\":13328,\"journal\":{\"name\":\"Immunotherapy\",\"volume\":\" \",\"pages\":\"723-732\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421297/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1750743X.2024.2353539\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2024.2353539","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:流行病学发现,人类白细胞抗原(HLA)等位基因的固有变异会影响自身免疫性疾病的发生。因此,HLA等位基因也可能与免疫相关不良事件(irAE)的发生有关,如甲状腺irAE。材料与方法:在这项病例对照研究中,共招募了71名接受免疫检查点抑制剂治疗的癌症患者,对他们进行了HLA基因分型,并比较了HLA等位基因的频率。结果显示甲状腺irAE患者中A*26:01、DPA1*01:03和DPB1*02:01的频率明显高于无irAE患者(分别为35.0 vs 3.2% [p = 0.004]、80.0 vs 45.2% [p = 0.020]和55.0 vs 25.8% [p = 0.044])。结论A*26:01、DPA1*01:03和DPB1*02:01似乎与甲状腺虹膜异位症有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event.

Aim: Inherent variations in human leukocyte antigen (HLA) alleles have been revealed epidemiologically to influence the development of autoimmune diseases. HLA alleles may thus also be associated with the development of immune-related adverse events (irAEs), such as thyroid irAE.Materials & methods: In this case-control study, 71 cancer patients who received immune checkpoint inhibitors were enrolled and HLA-genotyped and the frequency of HLA alleles was compared.Results: A*26:01, DPA1*01:03 and DPB1*02:01 were significantly more frequent in patients with thyroid irAE than in patients without any irAEs (35.0 vs 3.2% [p = 0.004], 80.0 vs 45.2% [p = 0.020] and 55.0 vs 25.8% [p = 0.044], respectively).Conclusion: A*26:01, DPA1*01:03 and DPB1*02:01 appear to be associated with thyroid irAE.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Immunotherapy
Immunotherapy 医学-免疫学
CiteScore
5.00
自引率
3.60%
发文量
113
审稿时长
6-12 weeks
期刊介绍: Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信